TABLE 2.
Drug | Isolate type | Geometric mean IC50 (nM) (SD; no. of samples) for yr |
P valuea | |||
---|---|---|---|---|---|---|
2010 | 2011 | 2012 | 2013 | |||
CQ | Clinical | 31.77 (4.5; 30) | 23.42 (4.5; 39) | 21.09 (4.9; 35) | 19.85 (7.1; 70) | 0.0061 |
3D7 | 21.32 (6.78; 25) | 16.28 (12.01; 42) | 19.77 (15.11; 23) | 17.79 (17.93; 53) | 0.111 | |
MQ | Clinical | 36.19 (5.5; 29) | 27.20 (6.4; 39) | 26.57 (10.2; 33) | 32.23 (8.4; 69) | 0.8896 |
3D7 | 77.39 (108.73; 25) | 34.96 (19.05; 42) | 36.89 (52.56; 23) | 36.64 (27.24; 55) | 0.428 | |
AQ | Clinical | 19.94 (4.0; 31) | 16.14 (4.0; 39) | 9.92 (5.9; 33) | 12.44 (8.6; 59) | 0.0576 |
ARS | Clinical | 2.76 (4.7; 30) | 4.08 (10.5; 38) | 1.74 (15.5; 34) | 0.78 (10.1; 71) | <0.0001 |
DHA | Clinical | 5.87 (10.1; 29) | 16.3 (14.9; 39) | 14.38 (21.3; 34) | 7.2 (10.7; 67) | 0.0028 |
3D7 | 9.14 (8.79; 18) | 19.69 (63.65; 41) | 13.36 (42.55; 19) | 7.03 (11.25; 55) | 0.159 |
The statistical test controlled for age and log-transformed parasite density, except for laboratory isolate 3D7.